NCT07397650

Efficacy and Safety With Early Treatment of Finerenone in Hospitalized Patients With Heart Failure

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 550 (estimated)
• Sponsor: Juntendo University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

FACILITATE-HF is a multicenter, randomized, double-blind, placebo-controlled trial designed to determine whether initiation of finerenone during the early phase of hospitalization has beneficial effects in patients with AHF who have left ventricular ejection fraction 40% or more.

Conditions

• Acute Heart Failure

Interventions

Type	Name	Description
DRUG	Finerenone Oral Tablet	For participants with an eGFR ≤60 mL/min/1.73 m\^2: Starting dose is 10 mg OD and maximum dose 20 mg OD. For participants with an eGFR \>60 mL/min/1.73 m\^2: Starting dose is 20 mg OD and maximum dose 40 mg OD.
DRUG	Finerenone Placebo	Placebo tablets matching finerenone are administered orally

Timeline

• Start date: 2026-02-01
• Primary completion: 2027-12-01
• Completion: 2028-09-30
• First posted: 2026-02-09
• Last updated: 2026-02-11

Locations

21 sites across 1 country: Japan